495 related articles for article (PubMed ID: 18535813)
1. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
Bidlingmaier S; Zhu X; Liu B
J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
[TBL] [Abstract][Full Text] [Related]
2. Research progression of CD133 as a marker of cancer stem cells.
Zhang H; Li SY
Chin J Cancer; 2010 Mar; 29(3):243-7. PubMed ID: 20193104
[TBL] [Abstract][Full Text] [Related]
3. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
4. CD133 as a marker for cancer stem cells: progresses and concerns.
Wu Y; Wu PY
Stem Cells Dev; 2009 Oct; 18(8):1127-34. PubMed ID: 19409053
[TBL] [Abstract][Full Text] [Related]
5. Two novel monoclonal antibodies against human CD133-2: distinct epitopes and agonist activity to enhance growth of CD133 expression cells in vitro.
Wang J; Li F; Zhang G; Chen Y; Hu Y; Chen X; Lu B; Zhang X
Hybridoma (Larchmt); 2010 Jun; 29(3):241-9. PubMed ID: 20569000
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma cells negative for the anti-CD133 antibody AC133 express a truncated variant of the CD133 protein.
Osmond TL; Broadley KW; McConnell MJ
Int J Mol Med; 2010 Jun; 25(6):883-8. PubMed ID: 20428792
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
8. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.
Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL
PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074
[TBL] [Abstract][Full Text] [Related]
9. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ
Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
Skubitz AP; Taras EP; Boylan KL; Waldron NN; Oh S; Panoskaltsis-Mortari A; Vallera DA
Gynecol Oncol; 2013 Sep; 130(3):579-87. PubMed ID: 23721800
[TBL] [Abstract][Full Text] [Related]
11. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
12. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
[TBL] [Abstract][Full Text] [Related]
13. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.
Kemper K; Sprick MR; de Bree M; Scopelliti A; Vermeulen L; Hoek M; Zeilstra J; Pals ST; Mehmet H; Stassi G; Medema JP
Cancer Res; 2010 Jan; 70(2):719-29. PubMed ID: 20068153
[TBL] [Abstract][Full Text] [Related]
14. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53.
Park EK; Lee JC; Park JW; Bang SY; Yi SA; Kim BK; Park JH; Kwon SH; You JS; Nam SW; Cho EJ; Han JW
Cell Death Dis; 2015 Nov; 6(11):e1964. PubMed ID: 26539911
[TBL] [Abstract][Full Text] [Related]
16. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells.
Lehnus KS; Donovan LK; Huang X; Zhao N; Warr TJ; Pilkington GJ; An Q
Int J Oncol; 2013 Mar; 42(3):1011-7. PubMed ID: 23340741
[TBL] [Abstract][Full Text] [Related]
17. Insight into the complex regulation of CD133 in glioma.
Campos B; Herold-Mende CC
Int J Cancer; 2011 Feb; 128(3):501-10. PubMed ID: 20853315
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody CD133-2 (AC141) against hematopoietic stem cell antigen CD133 shows crossreactivity with cytokeratin 18.
Pötgens AJ; Schmitz U; Kaufmann P; Frank HG
J Histochem Cytochem; 2002 Aug; 50(8):1131-4. PubMed ID: 12133915
[TBL] [Abstract][Full Text] [Related]
19. Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts.
Lang J; Lan X; Liu Y; Jin X; Wu T; Sun X; Wen Q; An R
Nucl Med Biol; 2015 May; 42(5):505-512. PubMed ID: 25669587
[TBL] [Abstract][Full Text] [Related]
20. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges.
Grosse-Gehling P; Fargeas CA; Dittfeld C; Garbe Y; Alison MR; Corbeil D; Kunz-Schughart LA
J Pathol; 2013 Feb; 229(3):355-78. PubMed ID: 22899341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
